Therapeutics and Clinical Risk Management

Scope & Guideline

Advancing medication safety through innovative research.

Introduction

Welcome to your portal for understanding Therapeutics and Clinical Risk Management, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN-
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationTHER CLIN RISK MANAG / Therap. Clin. Risk Manag.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

The journal "Therapeutics and Clinical Risk Management" focuses on disseminating high-quality research that addresses therapeutic strategies and the management of clinical risks associated with various medical conditions. Its scope encompasses a broad range of topics related to therapeutic interventions, clinical outcomes, and the optimization of patient care processes.
  1. Therapeutic Innovations and Evaluations:
    The journal publishes studies that explore new therapeutic modalities, drug efficacy, and safety profiles, ensuring that healthcare professionals are informed about the latest advancements in treatment options.
  2. Clinical Risk Assessment and Management:
    Research focusing on identifying and mitigating clinical risks, including adverse events and complications associated with medical interventions, is a core area of the journal.
  3. Patient-Centric Care Strategies:
    The journal emphasizes studies that evaluate patient outcomes, quality of life, and the impact of therapeutic approaches on patient populations, reflecting a commitment to patient-centered healthcare.
  4. Evidence-Based Medicine and Guidelines:
    Publications often include systematic reviews, meta-analyses, and guideline development to support evidence-based practice in clinical settings.
  5. Interdisciplinary Research:
    The journal encourages interdisciplinary studies that integrate pharmacology, surgery, nursing, and public health perspectives to address complex clinical challenges.
The journal has identified several emerging themes in recent publications, reflecting the evolving landscape of therapeutic and clinical risk management. These trends signify a response to contemporary healthcare challenges and innovations in treatment approaches.
  1. Integration of Machine Learning and AI in Healthcare:
    Recent studies increasingly focus on the application of machine learning algorithms to predict clinical outcomes and enhance decision-making processes in patient management.
  2. Personalized and Precision Medicine:
    There is a growing emphasis on research that tailors therapeutic interventions to individual patient profiles, particularly in oncology, cardiology, and chronic disease management.
  3. Telemedicine and Digital Health Solutions:
    The rise of telehealth has led to a surge in studies evaluating its effectiveness, patient satisfaction, and impact on healthcare delivery, especially post-COVID-19.
  4. Multidisciplinary Approaches to Complex Conditions:
    Research incorporating multidisciplinary teams to manage complex health conditions is gaining traction, reflecting the complexity of modern healthcare needs.
  5. Patient Safety and Quality Improvement Initiatives:
    An increasing number of publications are dedicated to strategies for enhancing patient safety and quality of care in clinical settings, indicating a heightened focus on risk management.

Declining or Waning

While the journal has maintained a robust focus on various therapeutic and clinical risk management aspects, certain themes have shown a decline in publication frequency or interest over recent years. This may reflect shifts in research priorities or emerging areas of focus within the medical community.
  1. Traditional Pharmacological Approaches:
    There has been a noticeable decrease in studies solely focused on traditional pharmacological treatments, possibly due to a growing interest in personalized medicine and novel therapeutic approaches.
  2. Single-Modal Interventions:
    Research concentrating on isolated treatment modalities without considering comprehensive care strategies is less prevalent, indicating a trend towards more integrative and holistic approaches.
  3. Longitudinal Studies in Chronic Conditions:
    The frequency of longitudinal studies examining chronic disease management has waned, possibly due to challenges in funding and patient retention, leading to fewer insights into long-term therapeutic effectiveness.
  4. Basic Science Research:
    Basic science studies that do not directly translate to clinical applications appear to be declining, as the journal prioritizes research with immediate relevance to clinical practice.
  5. Low-Risk Surgical Interventions:
    There is a diminishing number of publications focused on low-risk surgical procedures, as the journal seems to be shifting towards high-impact clinical studies with significant implications for patient outcomes.

Similar Journals

Iranian Journal of Pharmaceutical Research

Advancing pharmaceutical knowledge for a healthier tomorrow.
Publisher: BRIEFLANDISSN: 1735-0328Frequency: 4 issues/year

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

International Journal of Pharmacology

Empowering Scholars to Shape the Future of Pharmacology
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

PHARMACOTHERAPY

Fostering Excellence in Medical Pharmacology
Publisher: WILEYISSN: 0277-0008Frequency: 12 issues/year

PHARMACOTHERAPY, an esteemed journal published by WILEY, stands as a pivotal resource within the field of medical pharmacology. With its ISSN 0277-0008 and E-ISSN 1875-9114, this journal has been at the forefront of pharmacological research since its inception in 1981. Renowned for its rigorous peer-review process and impactful contributions, it currently holds a prestigious Q1 quartile ranking in the pharmacology category, underscoring its significance as a leading publication in the field. It ranks #40 out of 272 journals in Scopus, placing it in the top 15% percentile of its category. While not an open-access publication, PHARMACOTHERAPY remains committed to advancing knowledge and understanding in pharmacological sciences, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to improving therapeutic outcomes and drug utilization. Based in the United States, at 111 River St, Hoboken, NJ, the journal is poised to continue its impact through to 2024 and beyond, welcoming contributions that further the discourse in pharmacotherapy.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Innovating Medicine, One Study at a Time
Publisher: WILEY-HINDAWIISSN: 1368-5031Frequency: 1 issue/year

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE is a premier peer-reviewed academic journal published by WILEY-HINDAWI, dedicated to advancing the field of clinical medicine. With an ISSN of 1368-5031 and E-ISSN 1742-1241, this open access journal has been providing a platform for insightful research since its inception in 1997 and continues to contribute significantly to the medical community, as indicated by its Q2 ranking in Medicine (miscellaneous) for 2023 and its position in the top 15% of Scopus-ranked journals. The journal invites innovative studies, systematic reviews, and clinical trials, making it a critical resource for healthcare professionals, researchers, and students seeking to stay updated on the latest clinical practices. Based in the United Kingdom at Adam House, 3rd Fl, 1 Fitzroy Sq, London W1T 5HE, this journal supports open accessibility, enhancing the dissemination of vital research findings across the globe. Join the growing community of scholars who contribute to and benefit from this influential publication as it continues to shape the future of clinical practice.

CLINICAL THERAPEUTICS

Pioneering the future of drug development and clinical practice.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

Journal of Pharmaceutical Health Care and Sciences

Advancing pharmaceutical innovations for a healthier tomorrow.
Publisher: BMCISSN: 2055-0294Frequency: 1 issue/year

The Journal of Pharmaceutical Health Care and Sciences is a premier open access journal published by BMC that aims to advance the field of pharmaceutical sciences by providing high-quality research and comprehensive reviews across various domains including pharmacology, nursing, and healthcare. With an impact factor reflecting its relevance and rigor, the journal has established itself as a significant platform for disseminating knowledge since its inception in 2015. The journal is indexed in Scopus, currently holding a position in the Q3 quartile for medical pharmacology and Q2 quartile for nursing pharmacology, indicating its growing influence and reach in the scientific community. Based in the United Kingdom with a commitment to open access, the Journal of Pharmaceutical Health Care and Sciences ensures that all researchers, professionals, and students have free access to vital research that fosters innovation and improves healthcare outcomes worldwide. With a focus on collaborative and multidisciplinary approaches, the journal invites contributions that align with its objectives of enhancing health care delivery and pharmaceutical practices.

DRUGS & THERAPY PERSPECTIVES

Empowering Researchers and Practitioners in Drug Therapy
Publisher: SPRINGERNATUREISSN: 1172-0360Frequency: 12 issues/year

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

Expert Opinion On Drug Safety

Pioneering Insights for Safer Medications
Publisher: TAYLOR & FRANCIS LTDISSN: 1474-0338Frequency: 6 issues/year

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.

International Journal of Clinical Pharmacy

Fostering Global Collaboration in Clinical Pharmacy
Publisher: SPRINGERISSN: 2210-7703Frequency: 6 issues/year

The International Journal of Clinical Pharmacy, published by Springer, serves as a pivotal platform for advancing research in the fields of Pharmaceutical Science and Pharmacology. This esteemed journal, recognized for its significant impact with an impressive Q1 ranking in Pharmacy and multiple Q2 designations, provides a dedicated space for scholars and practitioners to share innovative findings and methodologies that enhance clinical pharmacy practices. With an international reach and publication spanning from 2011 to 2024, the journal aims to facilitate knowledge exchange among researchers, professionals, and students, ultimately contributing to improved therapeutic outcomes. As an open-access journal, it promotes widespread dissemination of vital research, ensuring that cutting-edge clinical pharmacy knowledge is accessible to all stakeholders in the healthcare continuum.

PHARMAZIE

Empowering innovation in pharmaceutical sciences.
Publisher: AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBHISSN: 0031-7144Frequency: 12 issues/year

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.